Brainstorm Cell Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Brainstorm Cell Therapeutics

28/03/2023 13:34

* Brainstorm Cell Therapeutics Inc  BCLI.OQ   BCLI.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 30. 
    * 
    * ​Refinitiv's mean analyst estimate for Brainstorm Cell
Therapeutics Inc is for a loss of 14 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $12.5​, above​ its last closing price
of $1.60. ​​​

This summary was machine generated March 28 at 12:34 GMT.  All
figures in US dollars  unless otherwise stated